Huberman Lab

Dr. Matthew Johnson on Huberman Lab: How Psilocybin Heals

Psilocybin reshapes self-identity to treat depression and addiction at high doses. Johnson covers clinical dosing, set and setting, and bad-trip risks.

AHAndrew HubermanhostMJDr. Matthew Johnsonguest

Jul 24, 2025·34m·Watch on YouTube ↗

📖 CHAPTERS

1. 1
   1:00 – 7:00

   Defining Psychedelics: Classes, Chemistry, And Receptor Targets

   Johnson lays out what qualifies as a psychedelic and why the term is more functional than pharmacologically precise. He distinguishes classic 5‑HT2A serotonergic psychedelics, NMDA antagonists, and MDMA, and describes how they converge on profoundly altering reality and self-perception.

2. 2
   7:00 – 13:00

   Models Of Reality, Prediction, And How Psychedelics Disrupt Them

   The conversation shifts to how psychedelics challenge internal models of reality and self, sometimes to extreme degrees. Johnson and Huberman discuss rare but real cases of people massively misjudging physical reality on psychedelics and why extracting general themes for novices is important.

3. 3
   13:00 – 19:40

   Serotonin, Contentment, And The Mystery Of Psychedelic Mechanisms

   Huberman and Johnson explore how serotonin and dopamine broadly shape contentment vs. action and how psychedelics, despite acting on serotonin receptors, diverge dramatically from normal serotonergic states. Johnson notes that receptor pharmacology is well described, but linking it to the complex subjective effects remains an open research frontier.

4. 4
   19:40 – 27:00

   Inside A Clinical Psilocybin Trial: Screening, Preparation, And Dosing

   Johnson walks through the process a participant would experience in a Johns Hopkins psilocybin trial, from psychiatric and cardiovascular screening to preparatory sessions and the dosing day itself. He emphasizes the importance of building trust with guides and thoroughly educating participants about the full range of possible experiences.

5. 5
   27:00 – 29:20

   Letting Go, Focused Perceptual Bubbles, And The Role Of Safety

   The discussion turns to the experiential dynamics of a high-dose session: narrow, intensified perceptual ‘bubbles’; the need to relinquish control; and why a safe container is essential. Johnson gives clinical anecdotes illustrating both the awe and the fear people can experience, and how guides support surrender and emotional expression.

6. 6
   29:20 – 38:00

   Changing Self-Representation: Identity Shifts In Depression And Addiction

   Johnson details how successful psychedelic therapy often produces enduring changes in self-identity—how people describe themselves and their agency. He illustrates this with stories from cancer patients and smokers, showing how a deeply felt realization of choice and responsibility can emerge during the session and persist afterward.

7. 7
   38:00 – 43:40

   MDMA, Trauma, And The Mechanics Of ‘Bad Trips’ Versus Mystical States

   The conversation compares MDMA’s profile with classic psychedelics and examines why MDMA may be especially well suited for trauma work. Johnson also explains how extremely challenging experiences under psilocybin or LSD relate to mystical, unity-type experiences, and how surrender vs. resistance shapes whether a session feels like a ‘bad trip.’

8. 8
   43:40 – 47:40

   Risks, Destabilization, And Why Set And Setting Matter

   Huberman presses on dangers and boundaries, including use by young people and non-clinical users. Johnson outlines major risks—especially for those with psychotic vulnerabilities and for anyone at high doses without proper support—and quantifies how often ‘bad trips’ occur even in ideal settings.

9. 9
   47:40 – 53:00

   Microdosing: Claims, Current Evidence, And Likely Limits

   Johnson offers a critical assessment of microdosing, contrasting popular narratives with the actual data. He notes that controlled studies have not supported claims of improved creativity, cognition, or sustained mood, and explains what kinds of effects might still be plausible if future, better-designed trials are positive.

10. 10
    53:00

    Heroic Doses And The Frontier Of Brain Repair And Neuroplasticity

    In closing, Johnson contrasts his excitement about heroic-dose therapies with the more modest hopes for microdosing and then describes speculative applications to neurological injury. He connects animal data on psychedelic-induced neuroplasticity with human anecdotes from head-injured athletes, outlining future research to test whether psilocybin can improve depression and cognitive measures in this population.